A New Measure of Child-Reported Symptomatic Toxicities of Cancer Treatment: Introducing Pediatric PRO-CTCAE^®

Purpose

NCI’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE^®) was developed to capture symptomatic toxicity by patient self-report in cancer clinical trials. A pediatric version of PRO-CTCAE (Ped-PRO-CTCAE^®) is now available to enable self-reporting of symptomatic adverse events by children and adolescents.

In this webinar speakers and discussants

• Describe the design and psychometric testing of Ped-PRO-CTCAE^®
• Demonstrate the creation of customized PRO-CTCAE^® surveys
• Highlight the value of this new measure for pediatric oncology trials

Intended Audience

Extramural investigators at junior, mid, and senior levels.

Suggested Readings

• Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Am Soc Clin Oncol Educ Book 2016;35:67-73. doi: 10.14694/EDBK_159514
• Reeve BB et al. Pediatr Blood and Cancer 2017;64(3):1-7. DOI: 10.1002/pbc.26261.
• Reeve BB et al. JNCI. Published online first. https://doi.org/10.1093/jnci/djaa016